AstraZeneca’s AZD5462 revives interest in relaxin-based heart-failure treatment on September 01, 2026 2026 AstraZeneca AZD5462 cardiac remodeling ESTERASE C Heart failure LUMINARA Phase IIb Relaxin RXFP1 gene Vasodilation +